Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease

Aim. To investigate endothelial dysfunction (ED) in patients with coronary heart disease (CHD), stable effort angina, Functional Class (FC) I-III, as well as to study perindopril potential in ED correction.Material and methods. The study included 37 CHD patients (22 men, 15 women; mean age 62,2+5,3...

Full description

Saved in:
Bibliographic Details
Main Authors: O. A. Vartanova, N. V. Mikhailova, T. E. Morozova
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2008-06-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1378
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849689436891119616
author O. A. Vartanova
N. V. Mikhailova
T. E. Morozova
author_facet O. A. Vartanova
N. V. Mikhailova
T. E. Morozova
author_sort O. A. Vartanova
collection DOAJ
description Aim. To investigate endothelial dysfunction (ED) in patients with coronary heart disease (CHD), stable effort angina, Functional Class (FC) I-III, as well as to study perindopril potential in ED correction.Material and methods. The study included 37 CHD patients (22 men, 15 women; mean age 62,2+5,3 years) with FC I-II (n=22) and FC III angina (n=15). The control group included 16 healthy individuals. Fndothelium-dependent vasodilatation (FDVD) of brachial artery (BA) was assessed in reactive hyperemia test at baseline and after 6 weeks of perindopril therapy (8 mg/d); in controls, FDVD was assessed at baseline only.Results. At baseline, ED was observed in 79 % of CHD patients: in 42 %, as an inadequate vasodilatation effect (< 10 % from the baseline), and in other 37 %, as no BA diameter increase or vasoconstriction. ED was more prevalent in individuals with FC III angina (93 %) than in participants with FC I-II angina (69 %). Perindopril therapy was associated with increased numbers of patients with vasodilatation > 10 % (+9 %)or<10 % (+3,5 %), while the number of participants with vasoconstriction reduced by 12,5 %. The number of ED participants reduced by 26 % and 8 % for FC I-II and FC III, respectively. Among those with FC I-II angina, perindopril treatment was associated with significant increase in BA diameter (+9,8 %; p<0,05), linear and volumic blood flow velocity (from 15,0+1,9 to 41,5+2,1 cm/s (p<0,05) and from 2,1+0,5 to 6,9+0,5 ml/s (p<0,05), respectively).Conclusion. Adding perindopril (8 mg/d) to standard anti-ischemic therapy was associated with reduced ED, which could be regarded as a vasoprotective perindopril effect.
format Article
id doaj-art-60b2b6210d354ff2b4e485d2d1f204ae
institution DOAJ
issn 1728-8800
2619-0125
language Russian
publishDate 2008-06-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-60b2b6210d354ff2b4e485d2d1f204ae2025-08-20T03:21:39Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252008-06-017340451088Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart diseaseO. A. Vartanova0N. V. Mikhailova1T. E. Morozova2I.M. Sechenov Moscow Medical Academy. MoscowI.M. Sechenov Moscow Medical Academy. MoscowI.M. Sechenov Moscow Medical Academy. MoscowAim. To investigate endothelial dysfunction (ED) in patients with coronary heart disease (CHD), stable effort angina, Functional Class (FC) I-III, as well as to study perindopril potential in ED correction.Material and methods. The study included 37 CHD patients (22 men, 15 women; mean age 62,2+5,3 years) with FC I-II (n=22) and FC III angina (n=15). The control group included 16 healthy individuals. Fndothelium-dependent vasodilatation (FDVD) of brachial artery (BA) was assessed in reactive hyperemia test at baseline and after 6 weeks of perindopril therapy (8 mg/d); in controls, FDVD was assessed at baseline only.Results. At baseline, ED was observed in 79 % of CHD patients: in 42 %, as an inadequate vasodilatation effect (< 10 % from the baseline), and in other 37 %, as no BA diameter increase or vasoconstriction. ED was more prevalent in individuals with FC III angina (93 %) than in participants with FC I-II angina (69 %). Perindopril therapy was associated with increased numbers of patients with vasodilatation > 10 % (+9 %)or<10 % (+3,5 %), while the number of participants with vasoconstriction reduced by 12,5 %. The number of ED participants reduced by 26 % and 8 % for FC I-II and FC III, respectively. Among those with FC I-II angina, perindopril treatment was associated with significant increase in BA diameter (+9,8 %; p<0,05), linear and volumic blood flow velocity (from 15,0+1,9 to 41,5+2,1 cm/s (p<0,05) and from 2,1+0,5 to 6,9+0,5 ml/s (p<0,05), respectively).Conclusion. Adding perindopril (8 mg/d) to standard anti-ischemic therapy was associated with reduced ED, which could be regarded as a vasoprotective perindopril effect.https://cardiovascular.elpub.ru/jour/article/view/1378coronary heart diseaseendothelial dysfunctionperindopril
spellingShingle O. A. Vartanova
N. V. Mikhailova
T. E. Morozova
Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease
Кардиоваскулярная терапия и профилактика
coronary heart disease
endothelial dysfunction
perindopril
title Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease
title_full Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease
title_fullStr Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease
title_full_unstemmed Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease
title_short Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease
title_sort endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease
topic coronary heart disease
endothelial dysfunction
perindopril
url https://cardiovascular.elpub.ru/jour/article/view/1378
work_keys_str_mv AT oavartanova endothelialdysfunctionanditscorrectionwithperindopriltherapyinpatientswithcoronaryheartdisease
AT nvmikhailova endothelialdysfunctionanditscorrectionwithperindopriltherapyinpatientswithcoronaryheartdisease
AT temorozova endothelialdysfunctionanditscorrectionwithperindopriltherapyinpatientswithcoronaryheartdisease